During the 2025–26 interim, Legislative Management studies possible data reporting rules for drug discount program participants and reports recommendations to the seventieth legislative assembly.
During the 2025–26 interim, Legislative Management studies whether North Dakota should require federal drug discount program participants to report data and how that data could help patients.
Legislative Management studies whether North Dakota should require participants to report data and how the state could use it to shape policy that directly benefits patients. The study covers North Dakota participants in the federal drug discount program, including health care facilities, pharmacies, health centers, drug makers, pharmacy benefit managers, and health insurers. The study considers which participating organizations should report, what data they should provide, and how the state could collect and share it. It also considers privacy, disclosure, and possible civil penalties for failing to report, with input from listed health care groups, organizations, and state agencies. The study takes place during the 2025–26 interim. Legislative Management reports its findings, recommendations, and any needed legislation to the seventieth legislative assembly.
No hearings or votes scheduled.